MoonLake’s Psoriatic Arthritis Drug Shows Promise In Phase 3 Trial – Retail Shrugs Off Premarket Slide, Says ‘Pipeline Is Intact’

At week 16, 42.1% of patients on Sonelokimab achieved at least a 50% improvement in psoriatic arthritis symptoms, meeting the ...

Tenax Therapeutics Phase 3 LEVEL Trial Misses Primary Endpoint for TNX-103

The pivotal study failed to show a statistically significant improvement in exercise capacity or its key secondary symptom ...
Fierce Pharma

Unapproved in US for decades, levosimendan stumbles in phase 3 as Tenax eyes narrow FDA path

Nearly three decades after its failed bid for FDA approval, the cardiovascular drug levosimendan is still struggling to ...

Bright Minds: BMB-101 Takes Center Stage Ahead Of Phase 3 Pivotal Trials

BMB-101 targets drug-resistant epilepsies with strong Phase 2 results and a differentiated safety profile, but Phase 3 risks ...

EyePoint: Phase 3 Design Creates A More Valuable Durability Story

Ocular Therapeutix's AXPAXLI is the closest investigational competitor. Ocular Therapeutix recently announced positive Phase ...
The Manila Times

MoonLake Announces Positive Topline Results from the Phase 3 IZAR-1 Trial of Sonelokimab in Psoriatic Arthritis Demonstrating Significant Improvements Across all Clinical ...

The primary endpoint of ACR50 was met with a high response of 42.1% for sonelokimab’s 60 mg with induction, and significant responses were observed across key secondary endpoints, including ACR20 ...